# ALEXIUM

ALEXIUM INTERNATIONAL GROUP LIMITED APPENDIX 4E PRELIMINARY FINAL REPORT For the Year Ended 30 June 2022

ABN 91 064 820 408 PRESENTED IN US DOLLARS

### 1.0 Reporting Period

Year ending 30 June 2022

Previous corresponding period: Year ending 30 June 2021

2.1	Revenue from ordinary activities	up	12.3%	to	8,174,937
2.2	Loss from ordinary activities for the period after tax attributable to members	up	(132.5%)	to	(3,360,271)
2.3	Net loss for the period attributable to members	up	(132.5%)	to	(3,360,271)

2.4	Dividends	Amount per security	Franked amount per security
6	Interim dividend declared this period	Nil	Nil
$\mathcal{Y}$	Interim dividend declared and paid in previous corresponding period	Nil	Nil
2.5	Record date for determining entitlements to the dividends	N/A	

Brief explanation of any figures reported above to enable the figures to be understood:

Refer to Annual Report

## 3. Consolidated Statement of Comprehensive Income

- 🌰

Revenue		
	US\$	US\$
	8,174,937	7,276,39
Cost of sales	(4,845,222)	(4,634,49)
Gross Profit	3,329,715	2,641,90
Other Income	-	921,33
Administrative expenses	(3,365,866)	(3,388,08
Sales and marketing expenses	(846,727)	(1,058,57
Research and development costs	(1,177,513)	(814,22
Impairment of Intangibles	(1,026,377)	
Other expenses	(187,704)	(116,28
Operating expenses	(6,604,186)	(5,377,17
Loss before finance costs	(3,274,471)	(1,813,95
Interest expense	(776,042)	(681,86
Gain/ (Loss) on embedded derivative	688,060	1,043,9
Interest earned	2,182	6,5
Total finance costs	(85,800)	368,6
Loss before tax	(3,360,271)	(1,445,31
Tax expense	-	
Loss for the year after tax	(3,360,271)	(1,445,31
Other comprehensive income - Exchange differences on translation of foreign operations		
which may subsequently be reclassified to profit or loss	276,138	(233,64
Total comprehensive loss for the year	(3,084,133)	(1,678,96
Loss for the year attributable to members of the group	(3,360,271)	(1,445,31
Total comprehensive loss for the year attributable to members of the group	(3,084,133)	(1,678,96
Basic and diluted loss per share (cents)	(0.52)	(0.2

.

## 4. Consolidated Statement of Financial Position

	2022	2021
	US\$	US\$
Current Assets		
Cash and cash equivalents	1,027,095	2,932,67
Trade and other receivables	579,052	1,367,59
Inventories	1,599,220	1,224,09
Other current assets	90,504	74,84
Total Current Assets	3,295,871	5,599,19
Non-Current Assets		
Other financial assets	16,672	17,68
Property, plant and equipment	967,589	1,055,78
Intangible assets	1,569,167	2,961,41
Right of use asset	574,606	846,10
Total Non-Current Assets	3,128,034	4,880,97
Total Assets	6,423,905	10,480,17
Current Liabilities		
Trade and other payables	816,422	1,892,52
Lease liabilities	118,253	81,22
Borrowings	178,626	
Total Current Liabilities	1,113,301	1,973,74
Non-Current Liabilities		
Borrowings	2,815,195	2,510,34
Derivative liability	182,452	949,12
Lease liabilities	737,273	868,56
Total Non-Current Liabilities	3,734,920	4,328,03
Total Liabilities	4,848,222	6,301,77
Net Assets	1,575,683	4,178,39
Equity		
Contributed equity	66,523,851	66,265,39
Reserves	(1,195,699)	(1,694,804
Accumulated losses	(63,752,468)	(60,392,197
Total Equity	1,575,684	4,178,39

### 5. Consolidated Statement of Cash Flows

	2022	2021
	US\$	US\$
Cash flow from operating activities		
Receipts from customers and other income	8,924,204	7,041,916
Payments to suppliers and employees	(10,246,599)	(8,136,774)
Interest received	2,167	5,586
Interest and other costs of finance paid	(275,535)	(330,539)
Goods & services tax received	24,184	28,044
Net cash flows (used in) operating activities	(1,571,578)	(1,391,766)
Cash flows from investing activities		
Purchase of property, plant, and equipment	(52,380)	(112,463)
Payments for development costs	(302,437)	(774,033)
Proceeds from disposal of property, plant and equipment	· · · · ·	4,945
Net cash flows (used in) investing activities	(354,817)	(881,552)
Cash flows provided by financing activities		
Proceeds from borrowings	251,075	468,427
Transaction costs related to issues of shares	(4,285)	(2,189)
Transaction costs related to loans and borrowings	(57,768)	-
Repayment of borrowings	(114,708)	(143,265)
Net cash flows (used in) financing activities	74,314	322,973
Net (decrease) in cash and cash equivalents	(1,852,082)	(1,950,345)
Cash and cash equivalents at beginning of year	2,932,673	4,741,251
Effect of exchange rate changes on cash and cash equivalents	(53,496)	141,767
Cash and cash equivalents at end of year	1,027,095	2,932,673

### 6. Consolidated Statement of Changes in Equity

Transactions with owners in their capacity

Expiration of outstanding options

Share appreciation rights expense

Performance rights issued

Balance at 1 July 2021	Contributed Equity \$ 66,265,398	Options & Warrants Reserve \$ 83,934	Performance Rights Reserve \$ 221,783	Foreign Currency Translation Reserve \$ (2,000,521)	Consolidated Accumulated Losses \$ (60,392,197)	Total \$ 4,178,397
Balance at 1 July 2021	00,205,558	05,554	221,785	(2,000,521)	(00,392,197)	4,178,397
Loss for the period	-	-	-	-	(3,360,271)	(3,360,271)
Foreign currency translation	-	-	-	276,138	-	276,138
Total comprehensive income / (loss)	-	-	-	276,138	(3,360,271)	(3,084,133)
Transactions with owners in their capacity						
as owners:						
Capital raising costs	(4,284)	-	-	-	-	(4,284.45)
Share appreciation rights expense	-	-	293,799	-	-	293,799
Performance rights expense	-	-	9,075	-	-	9,075
Performance rights exercised	79,907	-	(79,907)	-	-	-
Share-based payments in lieu of salary	38,250	-	-	-	-	38,250
Share-based payments for services	144,580	-	-	-	-	144,580
Balance at 30 June 2022	66,523,851	83,934	444,750	(1,724,383)	(63,752,468)	1,575,684
Balance at 1 July 2020	65,943,807	726,070	113,569	(1,766,875)	(59,589,014)	5,427,557
						-
Loss for the period	-	-	-	-	(1,445,319)	(1,445,319)
Foreign currency translation	-	-	-	(233,646)	-	(233,646)
Total comprehensive income / (loss)	-	-	-	(233,646)	(1,445,319)	(1,678,965)

(642,136)

83,934

-

-

(2,000,521)

141,876

79,907

(113,569)

221,783

(17,364)

113,569

74,250

151,136

66,265,398

-

\_

642,136

(60,392,197)

-

(17,364)

141,876

79,907

74,250

151,136

4,178,397

-

Performance rights exercised Share-based payments in lieu of salary Share-based payments for services Balance at 30 June 2021

as owners:

Capital raising costs

## 7.0 Dividends

7.0	Dividends			
	Date dividend is payable			Not applicable
	Record date to determine entitlement			Not applicable
	If it is a final dividend, has it been declared?			Not applicable
>>				
				Amount per
		Amount	Franked amount	security of
		per	per security at	foreign source

				Not applicable
		Amount per security	Franked amount per security at 30%	Amount per security of foreign source dividend
8.0	Final dividend: Current year	Nil	Not applicable	Not applicable
	Interim dividend: Current year	Nil	Not applicable	Not applicable
			Current period	Previous period
	Ordinary securities		Not applicable	Not applicable
	Preference securities		Not applicable	Not applicable
9.0	Net tangible asset backing		2022	2021
((/))	Net tangible asset backing (deficiency) per ordinary share		US 0.00 Cents	US 0.19 Cents

# 10. Details of entities over which control has been gained or lost during the period, including the following.

Not applicable

IFRS

# 11. Details of associates and joint venture entities including the following.

Not applicable

## 12. Any other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.

Refer to annual report

# 13. Foreign entities set of accounting standards used in compiling the report (IAS)

# 14. Commentary on the results for the period

Refer to annual report

14.1	Earnings per share (EPS)	2022	2021
	Basic loss per share (cents)	(0.52)	(0.23)
14.2	Returns to shareholders	2022	2021
	Ordinary securities	-	-
	Preference securities	-	-
	Other equity instruments	-	-
	Total	-	-

# 15. Compliance statement

This report is based on accounts to which one of the following applies:

The accounts have been audited.

The accounts are in the process of being audited or subject to review.

- The accounts have been subject to review.
- The accounts have not yet been audited or reviewed.

Sign here: .....

..... Dr. Robert Brookins **Chief Executive Officer** 

Date: 26 August 2022